[go: up one dir, main page]

SG11201906671SA - Compositions and methods for inhibiting reticulon 4 - Google Patents

Compositions and methods for inhibiting reticulon 4

Info

Publication number
SG11201906671SA
SG11201906671SA SG11201906671SA SG11201906671SA SG11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA
Authority
SG
Singapore
Prior art keywords
international
co7c
compositions
methods
oakland
Prior art date
Application number
SG11201906671SA
Inventor
Daniel Nomura
James Olzmann
Leslie Bateman
Truc Nguyen
David Miyamoto
Tucker Huffman
Allison Roberts
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of SG11201906671SA publication Critical patent/SG11201906671SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WI P0 I P C T olimion °nolo DID Ho mil 01O 1110110111110 oimIE (10) International Publication Number WO 2018/144870 Al (51) International Patent Classification: A61K 31/275 (2006.01) CO7C 255/23 (2006.01) A61K 31/277 (2006.01) CO7C 255/31 (2006.01) A61P 35/00 (2006.01) CO7C 317/32 (2006.01) (21) International Application Number: PCT/US2018/016650 (22) International Filing Date: 02 February 2018 (02.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/454,681 03 February 2017 (03.02.2017) US 62/471,865 15 March 2017 (15.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventors: NOMURA, Daniel, K.; 4532 Davenport Av- enue, Berkeley, CA 94619 (US). OLZMANN, James, A.; 2269 Mastlands Drive, Oakland, CA 94611 (US). BATE- MAN, Leslie, A.; 51 Hancock Street, #12B, Boston, MD 02114 (US). NGUYEN, Truc, B.; 660 Kinkead Way, Apt. 201, Albany, CA 94706 (US). MIYAMOTO, David, K.; 380 Green St., Cambridge, MA 02139 (US). HUFFMAN, Tucker, R.; 1821 Sapphire Way, El Dorado Hills, CA 95762 (US). ROBERTS, Allison, M.; 523 Coventry Rd, Kensington, CA 94707 (US). (74) Agent: TERRANOVA, Zachary, L. et al.; Mintz Levin Cohn Ferris Glovsky Popeo, P.C., One Financial Center, Boston, MA 02111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 FIG. 1D 8W620 cell pathogen survival proliferation (57) : Disclosed herein, inter alia, are compositions and methods useful for inhibiting reticulon 4(RTN4). [Continued on next page] C WO 2018/144870 Al MIDEDIMOMMIDIREEMOMOEMOIFICIMMOVOIMIE Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
SG11201906671SA 2017-02-03 2018-02-02 Compositions and methods for inhibiting reticulon 4 SG11201906671SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762454681P 2017-02-03 2017-02-03
US201762471865P 2017-03-15 2017-03-15
PCT/US2018/016650 WO2018144870A1 (en) 2017-02-03 2018-02-02 Compositions and methods for inhibiting reticulon 4

Publications (1)

Publication Number Publication Date
SG11201906671SA true SG11201906671SA (en) 2019-08-27

Family

ID=63040209

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906671SA SG11201906671SA (en) 2017-02-03 2018-02-02 Compositions and methods for inhibiting reticulon 4

Country Status (11)

Country Link
US (1) US20200062696A1 (en)
EP (1) EP3576728A4 (en)
JP (1) JP2020506935A (en)
KR (1) KR20190126074A (en)
CN (1) CN110461322A (en)
AU (1) AU2018215447A1 (en)
BR (1) BR112019016132A2 (en)
CA (1) CA3051587A1 (en)
MX (1) MX2019009200A (en)
SG (1) SG11201906671SA (en)
WO (1) WO2018144870A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019325306A1 (en) * 2018-08-24 2021-02-18 Xeniopro GmbH Phenoxy(hetero)aryl ethers of antiproliferative activity
CA3162348A1 (en) * 2019-12-24 2021-07-01 Nathanael S. Gray Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
CN119318708B (en) * 2024-10-15 2025-10-10 中国科学技术大学 Application of EYA3 as a target in the treatment of cervical cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102790A (en) * 1991-09-17 1996-01-31 Roussel Uclaf 3-Cycloalkyl-prop-2- enamide derivatives
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
WO2006125208A1 (en) * 2005-05-19 2006-11-23 Wayne State University Inhibitors of matrix metalloproteinases
US8828390B2 (en) * 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
WO2012164103A2 (en) * 2011-06-03 2012-12-06 Universität Zürich Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair
WO2013020014A1 (en) * 2011-08-03 2013-02-07 National Taiwan University Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
CN104203242B (en) * 2012-04-04 2017-03-15 杭州德润玉成生物科技有限公司 Substituted quinolines as Bruton's tyrosine kinase inhibitors
EP3033625B1 (en) * 2013-08-13 2020-01-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
KR102408123B1 (en) * 2014-02-28 2022-06-10 고쿠리츠다이가쿠호진 도호쿠다이가쿠 Amide derivatives
CN106414397B (en) * 2014-04-16 2019-02-12 南洋理工大学 Allenamides as Orthogonal Handles for Selective Modification of Cysteines in Peptides and Proteins
MX2017009571A (en) * 2015-01-23 2018-09-27 Aclaris Therapeutics Inc Heterocyclic itk inhibitors for treating inflammation and cancer.
WO2017070611A1 (en) * 2015-10-22 2017-04-27 The Scripps Research Institute Cysteine reactive probes and uses thereof

Also Published As

Publication number Publication date
AU2018215447A1 (en) 2019-08-08
CN110461322A (en) 2019-11-15
MX2019009200A (en) 2019-10-21
WO2018144870A8 (en) 2019-09-06
BR112019016132A2 (en) 2020-04-07
CA3051587A1 (en) 2018-08-09
KR20190126074A (en) 2019-11-08
US20200062696A1 (en) 2020-02-27
EP3576728A4 (en) 2020-08-12
WO2018144870A1 (en) 2018-08-09
JP2020506935A (en) 2020-03-05
EP3576728A1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201900501RA (en) Cannabis composition
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201906395PA (en) Blockchain based data processing method and device
SG11201900596XA (en) Cannabis composition
SG11201804041QA (en) High conductivity graphane-metal composite and methods of manufacture
SG11202000131VA (en) Substituted aluminum nitride for improved acoustic wave filters
SG11201902857SA (en) Activatable anti-ctla-4 antibodies and uses thereof
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201803906PA (en) Control of cellular redox levels
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201907857RA (en) Edible and biodegradable utensils
SG11201806992VA (en) Antibodies to tigit
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201805493YA (en) Binding members with altered diversity scaffold domains
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201900665VA (en) Cannabis composition
SG11201807770RA (en) Sequence arrangements and sequences for neoepitope presentation
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201809395XA (en) Executable logic for processing keyed data in networks